Regulatory FDA seeks permanent future for rare pediatric priority review vouchers Pharmaceutical TechnologyThe rare disease framework has had a turbulent past few years, with the FDA looking to create regulatory stability.RegulatoryRare DiseaseRead full story pharminent April 9, 2026 (Last updated: April 9, 2026) Pharmaceutical Technology The rare disease framework has had a turbulent past few years, with the FDA looking to create regulatory stability. RegulatoryRare DiseaseRead full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Syneron raises $150m for macrocyclics, and other financingsNext: Jeito Capital secures over $1.2bn for new biopharma investments Related Stories Regulatory Outlook Therapeutics Secures FDA Approval for LYTENAVA pharminent July 31, 2026 Regulatory Outlook finally claims FDA approval for AMD drug pharminent July 27, 2026 Regulatory Outlook Therapeutics wins FDA approval for Lytenava in wet AMD pharminent July 27, 2026
